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Introduction
In 2013, the Centers for Disease Control (CDC) issued
antimicrobial resistance guidance ranking carbapenemresistant Enterobacteriaceae (CRE), Neisseria gonorrhea,
and Clostridium difficile as the three most urgent resistance
threats in the United States [1]. CRE are defined as pathogens
testing resistant to the following carbapenem antimicrobials
(imipenem, meropenem, doripenem, or ertapenem) or are
documented to produce a carbapenemase [2]. In the 2013
CDC report, an estimated 9,300 inpatient cases were predicted
annually, and as of December 2017, CRE isolates have now
been reported in all 50 states [3]. Enterobacteriaceae cause
roughly 27.2% of healthcare-associated infections (HAIs) in
acute care settings, with Klebsiella pneumoniae and E. coli
as the predominant species [4]. Carbapenems are useful last
line treatment options in multidrug-resistant gram-negative
infections. Therefore, CRE are truly a healthcare threat.

Classification of Carbapenemases
The most common mechanism of carbapenem resistance
is production of carbapenemases, beta-lactamase enzymes
conferring one of several mechanisms of carbapenem resistance.
It is important to note that not all carbapenemases are the same
and can be classified using either molecular structure (Ambler
classification) or functional activity (Bush-Jacoby-Medeiros
classification) [5]. Ambler classes A, B, and D comprise the
majority of carbapenemases and hydrolyze beta-lactams using
either a serine or zinc complex that cleaves the beta-lactam
ring and inactivates the antimicrobial. Among multidrugresistant gram-negative bacteria species, Enterobacteriaceae,
Pseudomonas aeruginosa, and Acinetobacter baumanii are all
carbapenemase-producing organisms (CPOs).
In the United States, Class A enzymes including the Klebsiella
pneumoniae carbapenemase (KPC) are widespread and
now considered endemic. KPCs have been documented
in several Enterobacteriaceae species including Klebsiella
pneumoniae, E. coli, Citrobacter sp., Enterobacter sp., and
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Serratia marcescens [6]. Using isolates from 2011 – 2015, a
96% prevalence of the KPC enzyme among all carbapenemases
in the United States was reported, and the KPC enzyme was
most commonly acquired by Klebsiella pneumoniae [7].
Luckily, several new combination beta-lactams utilizing novel
beta-lactamase inhibitors have been FDA approved in the
United States to combat Class A carbapenemases, notably
ceftazidime-avibactam
and
meropenem-vaborbactam.
Class B enzymes, or metallo-beta-lactamases (MBLs), are
more globally distributed outside of the Unites States.
They are characterized by the New Delhi metallo-betalactamase (NDM) endemic to India, Verona integrinencoded metallo-beta-lactamase (VIM) found in Europe,
and imipenemase metallo-beta-lactamase (IMP) in Asia
and Australia [8]. These carbapenemases are very difficult
to treat, as antimicrobial options are limited. To date
in the United States, only older antimicrobials such as
polymyxins, aminoglycosides, or glycylcyclines are available.
As noted above, Class C enzymes, commonly known as
cephalosporinases, do not confer carbapenem resistance are not
discussed in this article. Lastly, Class D enzymes are caused by
a variety of oxacillinase beta-lactamases (OXA) and are endemic
in northern Africa, eastern Europe, and India. An example is
the oxacillinase (OXA) enzyme subtype.

CRE Laboratory Detection
Accurate laboratory detection of carbapenemases is essential
to optimize patient care and facilitate timely infection control
prevention measures. In the United States, CRE isolates are
reportable to state health departments, with further tracking
by the CDC. Laboratories have faced challenges with accurately
identifying isolates. Some isolates tested susceptible to
carbapenems, however, carbapenem MICs were elevated. In
addition, some automated susceptibility testing systems failed to
detect low-level carbapenem resistance. In 2010, the Clinical and
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Laboratory Standards Institute (CLSI) lowered the carbapenem
breakpoints in an effort to facilitate detection and reporting
of carbapenem-resistant isolates. The US Food and Drug
Administration (FDA) shortly followed by updating medication
package inserts. With the current guidance, supplemental
testing outside of automated susceptibility testing instruments
(AST) is no longer recommended. Institutions using older
ASTs should update their equipment according to the newer
breakpoints. Humphries R, et al. validated the accuracy of
newer breakpoints to detect carbapenem-resistant isolates
by comparing to polymerase chain reaction (PCR) assay for a
variety of carbapenemase genes. Results indicated that few
PCR-proven carbapenemase-producing isolates were reported
as susceptible; <1% for ertapenem and imipenem, whereas
2.9% for meropenem [6]. Aside from AST, inaccuracies with the
modified Hodge test have led to development of more reliable
supplementary testing methodologies including the CarbaNP and carbapenem inactivation method. CLSI updates their
testing recommendations annually, so please refer to that
reference for the most up-to-date information.

CRE Infections
The 2013 CDC Urgent Threat Report identified the following
patients at high risk for antibiotic resistant infections;
immunocompromised patients (cancer chemotherapy, organ
and bone marrow transplant, rheumatoid arthritis), dialysis
patients, and complex surgical patients [1]. Closer examination
of CRE infection literature confirms that dialysis and renal
replacement therapy are indeed identifiable risk factors.
Other risk factors include intensive care unit (ICU) admission,
receipt of antimicrobials in the previous 90 days, cumulative
antimicrobial exposures in the current admission, healthcare
facility exposure/transfer, and poor functional status [9,10,11].
The impact of CRE infection on clinical outcomes is daunting.
Using data from the Consortium on Resistance Against
Carbapenems in Klebsiella and other Enterobacteriaceae
(CRACKLE) study, a prospective, multicenter, observational
cohort, Hauck et al. evaluated clinical outcomes in 260 CRE
Klebsiella pneumoniae patients with bloodstream infection
(BSI), pneumonia, and urinary tract infection (UTI) compared
to those with CRE colonization and no active infection. A twofold increase in excess mortality was observed in patients with
BSI and pneumonia (27% versus 12%), but not with UTI [12].
Other studies have described CRE BSI mortality rates between
40-70% [9]. A recent BSI study demonstrated that when
carbapenem resistance was caused by a carbapenemase enzyme
versus another resistance mechanism (ie, outer membrane
porin changes), outcomes were worse. Authors suggest that
carbapenemase-mediated resistance may be more virulent,
although specific virulence factors were not elucidated [13].
An international, multicenter, retrospective study including
256 cases of CRE infection described overall 28-day mortality
rates of 28.1%. A disparity was observed among severities of
infection; 17.3% mortality with cUTI and pyelonephritis, but
up to 44% with severe infections particularly with the following
comorbidities were present; renal failure, sepsis, and immunedeficiency [14]. The mortality data discussed in this section was
analyzed prior to the clinical use of newer agents that will be
discussed below.
Also using data from CRACKLE, Eilertson et al. compared
clinical outcomes in CRE-infected patients with healthy renal
function versus those with renal replacement therapy (RRT).
RRT patients are known from previous studies to have increased

risk of mortality and infectious complications caused by
multidrug-resistant pathogens including sepsis and pneumonia.
In this study, those infected with CRE had worse outcomes
than non-CRE RRT patients; 31% 28-day in hospital mortality
[15]. Satlin et al. describe mortality rates of 40% in solid organ
transplant and 65% of hematologic malignancy patients.
Due to the potential for devastating patient outcomes in an
immunocompromised population, the authors emphasize the
importance of active surveillance and antimicrobial stewardship
to aid in prevention of infection in these patients [16].

CRE Outbreaks
CRE isolates are a major focus of infection control programs
since carbapenemases, especially KPCs, can be shared via
mobile plasmids resulting in healthcare-associated institution
outbreaks. It is important to implement effective infection
control measures including contact isolation precautions, hand
hygiene, surveillance, patient isolation, and environmental
cleaning in patients with active or prior CRE infections [17]. In
2011, Detroit Medical Center reported an outbreak of colistinresistant NDM-producing Klebsiella pneumoniae involving
three institutions caused by patient-to-patient transmission
[18]. A rural Kentucky hospital reported a CRE outbreak
occurring in 2016 from the emergency room to a specific hospital
ward. During a 4-month period, the facility detected 23 CRE
cases including both KPC and NDM1 carbapenemases. Through
a CDC investigation, two observations were made; first, CRE
isolates can be spread from urban to rural healthcare settings,
and second, environmental cleaning carts (or any equipment
moving throughout the facility) can be modes of transmission
[19]. Outbreaks have been reported throughout the United
States involving duodenoscopes or ventilators, invasive devices
such as urinary catheters, hospital room sinks and bedrails, and
have been spread across healthcare networks involving acute
care and long-term acute care (LTAC) facilities [20,21].

CRE Treatment Options
CRE isolates are resistant to almost all beta-lactams leaving
few, and unfortunately older, drug classes with adequate
activity. Specifically, these older treatment options include
aminoglycosides, polymyxins, a glycylcycline, and fosfomycin
[22]. Table 1 provides dosing regimens and compares
advantages and disadvantages of these older agents. It is
important to note that polymyxin B and colistin (polymyxin
E) are not identical in their adverse effect or pharmacokinetic
profiles. At the time of publication, CLSI does not provide
interpretive criteria for polymyxins for Enterobacteriaceae, and
susceptibility testing for Pseudomonas aeruginosa is no longer
recommended via Etest gradient diffusion or disk diffusion
due to unreliable results [23]. Colistin methanesulfonate
(CMS), a prodrug, requires renal elimination then hydrolysis
for conversion to its active metabolite, colistin. This step is
greatly impacted by renal dysfunction leading to high inter- and
intra-patient variability in the serum concentrations of active
drug. In patients with healthy renal function, 80% of CMS is
eliminated in the urine before metabolism to the active drug
even occurs, leaving subtherapeutic serum concentrations for
non-urinary tract infections [24]. Polymyxin B is not impacted
by this metabolic process and should be considered as the
polymyxin of choice for systemic treatment of non-urinary
tract infections. With regards to adverse effects, polymyxin
B has also been shown to be less nephrotoxic to renal tubular
cells [25]. A meta-analysis comparing differences in mortality
and adverse effects between the two agents found no difference
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Table 1 Older Agents for Treatment of CRE

Antimicrobial Recommended Dosing
for CRE Infections

Advantages

Disadvantages

Colistin 1,2,3,4,5
(Polymyxin E)

¥ Extensive evidence
for use in cUTI
¥ Adjunctive
inhalation route for
HAP/VAP

¥ Pharmacokinetic disadvantages compared to
polymyxin B. Should only be used for
urinary tract infections
¥ Combination therapy required
¥ Optimal dosing uncertain
¥ Emergence of resistance
¥ Nephrotoxicity
¥ Lack of activity against Proteus sp. and
Serratia marcescens
¥ Unreliable antimicrobial susceptibility
testing

¥ Extensive evidence
for use in BSI, PNA,
and sepsis
¥ Adjunctive
inhalation route for
HAP/VAP

Combination therapy required
Optimal dosing uncertain
Avoid use in urinary tract infections
Emergence of resistance
Nephrotoxicity
Lack of activity against Proteus sp. and
Serratia marcescens
¥ Unreliable antimicrobial susceptibility
testing
¥ Bacteriostatic activity
¥ Black Box Warning for all-cause mortality
(2013)
¥ Increasing antimicrobial resistance
¥ Dose-dependent adverse effects (mostly GIrelated)
¥ Pharmacokinetic limitations (inadequate
serum concentrations for treatment of BSI)
¥ Lack of activity against Pseudomonas
aeruginosa
¥ Only available orally for treatment of lower
UTI in the United States
¥ Development of resistance with
monotherapy

¥

¥

¥
¥
Polymyxin B 2,5

¥

¥

Dosed in milligrams
versus international
units (14) at CMS
Weight-based and fixed
dose regimens have
been evaluated (see
reference 5)
Loading dose is
recommended
Requires dosage
adjustment in renal
impairment
Weight-based dose
regimens (mg/kg and
14/kg)
(see reference 5)
Loading dose is
reccommended

Tigecycline 6

100-200 mg IV x1, then
either 50 mg IV q12h or 100
mg IV q24h

¥ Stable against many
beta-lactamases

Fosfomycin
trometamol 7

3 g oral single-dose versus
every 48h x3 doses (UTI
only)

Gentamicin,
Amikacin 3

G: 7 mg/kg/day IV
A: 15 mg/kg/day IV

¥ Excellent urine
penetration
¥ Bactericidal against
CRE
¥ Generally welltolerated
¥ Bactericidal activity
¥ Most efficacious
option for cUTI
¥ Extended interval
dosing
¥ Inhalation route for
HAP/VAP

¥
¥
¥
¥
¥
¥

¥ Nephrotoxicity, ototoxicity
¥ Combination therapy required, unless cUTI

Definitions: BSI: bloodstream infections, cUTI: complicated urinary tract infections, PNA: pneumonia, HAP: hospital-acquired pneumonia,
VAP: ventilator-associated pneumonia
1.
Dosed using colistimethate sodium, the prodrug and manufactured formulation in the United States.
2.
Polymyxins have identical antimicrobial spectrum against gram-negative pathogens, including lack activity against Proteus sp. and Serratia marcescens.
3.
IDSA HAP/VAP Guidelines support use, but European HAP/VAP guidelines disagree citing inadequate pulmonary delivery via nebulization and lack of evidence.
Inhalation can be used for active infection in combination with a systemic agent, or as prophylaxis in cystic fibrosis patients. Kidd JM, et al. Novel pharmacotherapy for
the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. Exp Opin Pharmacother 2018;19(4):397-408
4.
Liu YY, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological
study. Lancet Infect Dis 2016;16(2):161-68
5.
Tsuji BT, et al. International Consensus Guidelines for the Optional Use of the Polymyxins: Endorsed by ACCP, ESCMID, IDSA, ISAP, SCCM, and SIDP. Pharmacotherapy.
2019 Jan; 39(1):10-39.
6.
Antimicrobial resistance of tigecycline to Pseudomonas aeruginosa represents a classwide lack in antimicrobial spectrum among all tetracyclines
7.
Karageorgopolous D, et al. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteremia: report of three cases. J Antimicrob
Chemother. 2012;67(11):2777-9
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in clinical outcomes, but an increase in nephrotoxicity with
colistin [26]. Future studies are needed to determine whether
pharmacokinetic differences truly translate to undesirable
patient clinical outcomes.
Alexander E, et al performed an international, multicenter
CRE review using isolates from 2013-2014 and found overall
antimicrobial resistance rates of greater than 80% to penicillins,
cephalosporins, aztreonam, fluoroquinolones (FQs), and
trimethoprim/sulfamethoxazole (TMP/SMX). The same CRE
isolate review found antimicrobial resistance rates of 80% to
tobramycin, 57.8% to amikacin, 43.1% to gentamicin, 37% to
tigecycline, 26.4% to polymyxins [14]. The isolates in this study
reflect an international summary of antimicrobial resistance
and may not predict regional antimicrobial resistance trends.
Antimicrobial stewardship programs (ASPs) have a profound
effect on local institution resistance patterns by closely
monitoring antimicrobial utilization. Luckily, newer betalactam agents and an aminoglycoside have been FDA approved
in the United States to combat these highly resistant pathogens.
Treatment strategies utilizing these older agents is complex,
and ongoing research regarding novel combination therapies
has helped to optimize therapies. Combinations utilizing
polymyxins, tigecycline, or aminoglycosides with or without
a carbapenem have been described with mixed results. The
polymyxins, aminoglycosides (except for treatment UTI), and
intravenous fosfomycin should always be used in combination
to prevent emergence of antimicrobial resistance. In a 2014
review of 20 studies using older agents to treat CRE infections,
mortality rates were lower when combination therapy was
utilized compared to monotherapy (27.4% vs. 38.7%; p < 0.001,
respectively). In addition, combination regimens containing
carbapenems resulted in the lowest mortality rates (18.8%) [27].
Other studies have found conflicting evidence regarding
combination therapies with older agents. A 2014 meta-analysis
of 692 patients described mortality rates for tigecycline-colistin
and carbapenem-colistin regimens of 64% and 67%. Due to lack
of statistically significant benefit of combination therapy in all
infection types, authors concluded that it may only be beneficial
in severely ill patients with severe infections [28]. Another
review of 661 KPC infection episodes in Italy illustrated that only
those patients with high-risk infection (defined as non-UTI) or a
meropenem MIC ≤8 mg/L. benefited from combination therapy
[29]. In a recent randomized, controlled trial of 406 patients
with pneumonia or bacteremia, Paul M et al evaluated colistin
alone versus colistin plus meropenem for carbapenem-resistant
gram-negative infections [30]. Although the majority of
infections in this study were caused by Acinetobacter baumanii
instead of CRE isolates, combination therapy was not superior
to monotherapy and resulted in an increase in adverse effects,
most notably diarrhea.
Knowing whether an isolate is interpreted as intermediate or
resistant to carbapenems is clinically relevant. Use of prolonged
infusions and combination therapy can be implemented
to overcome intermediate resistance and improve clinical
outcomes.
Trained antimicrobial stewardship experts
(physicians and pharmacists) are valuable resources for
antimicrobial selection and dosage optimization. In addition,
infectious disease consultation is associated with decreased
30-day readmission, mortality, length of stay, and overall cost,
particularly in patients with Staphylococcus aureus bacteremia
and multidrug-resistant gram-negative infections [31,32,33].

Newer Agents with CRE-Activity
Ceftazidime-avibactam (CAZ-AVI) is an intravenous
cephalosporin/beta-lactamase
inhibitor
combination.
Avibactam, a novel non-beta-lactam beta-lactamase inhibitor
(NB-BLI) diazabicyclooctane (DBO), is currently commercially
available as a combination agent with ceftazidime, and is also
being studied in combination with aztreonam and ceftaroline
[34]. CAZ-AVI inhibits Class A, C, and some D enzymes, but
is inactive against Class B MBLs. It is most clinically useful
for its activity against extended-spectrum beta-lactamases
(ESBLs) and KPC carbapenemases. In 2015, CAZ-AVI was FDA
approved for treatment of complicated urinary tract infections
including acute pyelonephritis (cUTI/AP) and complicated
intra-abdominal infections (cIAI) in addition to metronidazole.
In early 2018, CAZ-AVI also gained FDA approval for hospitalacquired pneumonia (HAP) and ventilator-associated
pneumonia (VAP). The pneumonia trial comparator was
meropenem 1g IV q8h [35]. CAZ-AVI should be administered
2.5g IV q8h infused over 2 hours, and a renal dosage adjustment
is required for patients with a creatinine clearance (CrCl) <50
ml/min. Reported adverse effects from Phase 3 trials are similar
to ceftazidime monotherapy.
Although patients infected with CRE-producing strains were
excluded from the cUTI, cIAI and pneumonia trials due to lack
of CRE activity with the comparator agents, newer clinical
experiences describe efficacy and use of combination therapy
for CRE infections. Two retrospective studies evaluated
clinical success and mortality rates in CRE patients treated
with CAZ-AVI. In both studies, Klebsiella pneumoniae was
the predominant strain. Shields RK, et al. evaluated 30-day
clinical success and mortality rates in thirty-seven cases. Fifty
percent were diagnosed with HAP or VAP, and 70% were treated
with monotherapy [36]. King et al, evaluated end of treatment
clinical success and mortality rates in sixty cases [37]. The
most common infection types were bacteremia, pneumonia,
and UTI, and 55% were treated with monotherapy. Between
the two studies, clinical success rates were similar regardless of
the timepoint, 59% and 65% respectively. Mortality rates were
also similar; in-hospital mortality 32%, and 30- and 90-day
mortality, 24% and 38%. CAZ-AVI resistance developed during
therapy in both studies. The King study found no statistically
significant difference in outcomes between monotherapy and
combination therapy.
Other studies have compared CAZ-AVI to alternative agents
for treatment of CRE infections. A comparative study between
CAZ-AVI-containing regimens and alternative regimens
(mostly combinations with carbapenems) in patients with
KPC-Klebsiella pneumoniae bacteremia demonstrated higher
clinical success rates (85% versus 37-48%, P = 0.04). 90-Day
mortality rates were lowest among patients receiving CAZAVI regimens.
Patients receiving combination regimens
containing an aminoglycoside or colistin experienced a higher
rate of nephrotoxicity [38]. Another comparative study (n = 137
patients), using data from the CRACKLE database, analyzed
efficacy, safety, and benefit-risk outcomes between CAZ-AVIand colistin-containing initial treatment regimens. Patients
had a greater probability of a better outcome in all categories
with initial treatment with CAZ-AVI versus colistin. Fourteen
(37%) patients were treated with monotherapy in the CAZ-AVI
arm [39].
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Table 2 Antimicrobial Pipeline for Treatment of CRE infections

Antimicrobial
Cefiderocol (CFDC)1,2,3

Drug Class
Siderophore
cephalosporin

Imipenem/cilastatinrelebactam (IMI-REL)

Carbapenem + NBBLI DBO

Aztreonam-avibactam
(ATM-AVI) 6

Monobactam + NBBLI DBO

4,5

Fosfomycin for injection Epoxide
7,8
antimicrobial

Indications

Notes

Phase 3 RCT cUTI/AP
¥ CFDC 2 g IV every 8 hr vs.
imipenem/cilastatin 1 g IV every 8
hr
¥ DOT 7-14 days
Phase 3 RCT HABP/VABP
¥ CFDC 2 g IV every 8 hr vs.
meropenem 2 g IV every 8h plus
linezolid 600 mg IV every 12 hr
¥ DOT 7-14 days
Phase 3 RCT HABP/VABP,
BSI/Sepsis, cUTI
¥ CFDC 2 g IV every 8 hr vs. best
available therapy for CRE
DOT 7-14 days
Phase 3 RCT cUTI, cIAI, or
HABP/VABP
¥ IMI-REL 500-250 mg IV every 6 hr
vs. imipenem/cilastatin 500 mg IV
every 6 hr plus colistin IV every 812 hr
¥ DOT 5-21 days (cUTI/cIAI) or 7-21
days (HABP/VABP)
Phase 3 RCT HABP/VABP
¥ IMI-REL 500-250 mg IV every 6 hr
vs. piperacillin/tazobactam 4.5 g IV
every 6 hr
¥ DOT 7-14 days
Phase 3 RCT cIAI, HABP/VABP
¥ ATM-AVI 6.5/2.1 g loading dose,
then 6/2 g daily divided every 8 hr
+/- metronidazole 500 mg IV every
8 hr vs. meropenem 1-2 g IV every
8h +/- colistin IV every 8-12 hr
Phase 2/3 RCT cUTI/AP
¥ Fosfomycin 6 g IV every 8 hr vs.
piperacillin/tazobactam 4.5 g IV
every 6 hr
¥ DOT 7 days, 14 days if bacteremia

¥ Active against all
carbapenemases
including Class B MBLs
¥ Adverse effects similar to
other cephalosporins
¥ Excellent activity against
Acinetobacter sp.

¥ Active against Class A, C,
and D carbapenemases
¥ Inactive against Class B
MBLs

¥ Active against Class A, C
and D carbapenemases
¥ Inactive against Class B
MBLs
¥ Active against Class A, C
and D carbapenemases
¥ Variable activity against
Class B MBLs
¥ Intravenous formulation
available in many
countries
¥ Dose optimization
studies are ongoing for
use in the United States
¥ Combination therapy
required

Definitions: RCT: randomized controlled trial, BSI: bloodstream infections, cUTI: complicated urinary tract infections, AP: acute pyelonephritis, HABP: hospital-acquired bacterial
pneumonia, VABP: ventilator-associated bacterial pneumonia, NB-BLI DBO: non-beta-lactam beta-lactamase inhibitor diazabicyclooctane, cIAI: complicated intra-abdominal
infection, DOT: duration of therapy
1.
Ito A, et al. In Vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agent Chemother
2018;62(1):e01454-17
2.
Portsmouth S, et al. Clinical response of cefiderocol compared with imipenem/cilastatin in the treatment of adults with complicated urinary tract infections with or without
pyelonephritis or acute uncomplicated pyelonephritis: results from a multicenter, double-blind, randomized study (APEKS-cUTI). Open Forum Infect Dis 2017;4(Suppl 1):S537
3.
Clinical study of S-649266 for the treatment of nosocomial pneumonia caused by gram-negative pathogens (APEKS-NP) [Internet] Identifier NCT03032380 Bethesda MD:
National Library of Medicine [cited 2018 May 14]
4.
Zhanel G, et al. Imipenem-relebactam and meropenem-vaborbactam: Two novel carbapenem-beta-lactamase inhibitor combinations. Drugs 2018 Jan;78(1):65-98
5.
Kidd JM, et al. Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. Expert
Opinion on Pharmacotherapy 2018;19(4):397-408
6.
A study to determine the efficacy, safety and tolerability of aztreonam-avibactam (ATM/AVI) +/- metronidazole versus meropenem +/- colistin for the treatment of serious
infections due to gram-negative bacteria. [Internet] Identifier NCT03329092 Bethesda MD: National Library of Medicine [cited 2018 May 14]
7.
Kaye K, et al. Intravenous fosfomycin (ZTI-01) for the treatment of complicated urinary tract infections including acute pyelonephritis: results from a multicenter,
randomized, double-blind Phase 2/3 study in hospitalized adults (ZEUS). Open Forum Infect Dis 2017;4(Suppl1):S528. #1845
8.
Karageorgopoulos DE, et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens. J Antimicrob
Chemother 2012;67(2):255-68
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Meropenem-vaborbactam (MVB) is an intravenous carbapenem/
beta-lactamase inhibitor combination. Vaborbactam is the first
non-beta-lactam boronic acid inhibitor with activity against
Class A and C beta-lactamases, and is inactive against Class B
MBLs. Similar to CAZ-AVI, MVB is also most clinically useful
for its activity against ESBLs and KPC carbapenemases [40].
In 2017, MVB was FDA approved for treatment of cUTI/AP
(TANGO-1 trial). The comparator was piperacillin-tazobactam,
and patients could be switched to oral levofloxacin to complete
treatment. Few CRE infections were included in this trial [41].
MVB 2g/2g IV should be administered every 8 hours infused
over 3 hours, and a renal dosage adjustment is required for
patients with a creatinine clearance (CrCl) <50 ml/min.
Reported adverse effects from Phase 3 trials are similar to
meropenem monotherapy.
The TANGO-2 trial is a Phase 3 study including patients with
CRE infection (59.7%). Patients with cUTI/pyelonephritis,
cIAI, bacteremia, nosocomial pneumonia were included,
and the comparator was “best available therapy” (BAT),
meaning one of the older anti-CRE agents discussed above
as monotherapy or in combination. Recognizing that CRE
patients have multiple comorbidities and are different than
typical study populations for these types of infections, study
investigators performed a retrospective review of patients with
CRE infections in order to better define study design enrollment
criteria [14]. Authors estimate that only 22% of the TANGO-2
study population would have met enrollment using traditional
criteria. As a result of the study, it is unique that the TANGO-2
study allowed immunocompromised patients, and those with
severe sepsis and renal insufficiency needing dialysis, although
these types of patients did not comprise the majority of those
enrolled. Enrollment in the BAT arm was discontinued early
when interim analysis revealed better outcomes in MVB-treated
patients; in CRE patients, clinical cure 57.1% versus 26.7%.
Despite promising clinical outcomes, minimum inhibitory
concentrations (MIC) increased in several MVB-treated isolates
[42,43].
Plazomicin (PZM) is an intravenous aminoglycoside
antimicrobial with activity against ESBL- and carbapenemaseproducing aerobic gram negative rods. It is stable against
aminoglycoside modifying enzymes that inactivate gentamicin,
tobramycin, and amikacin, and most carbapenemase classes,
including some activity against Class B MBLs (except NDM)
[44]. There is limited activity against Stenotrophomonas
maltophilia, Acinetobacter baumanii, and Pseudomonas
aeruginosa, and future studies are needed to determine
clinical utility for these pathogens.
In 2018, PZM gained
FDA approval for treatment of cUTI/AP (EPIC trial) [45]. The
comparator was meropenem 1g IV q8h as a 30 minute infusion,
and a switch to an oral agent was allowed at 4 days. PZM was
studied using extended interval dosing, 15 mg/kg IV once daily
over 30 minutes, and a renal dosage adjustment is required for
patients with a creatinine clearance (CrCl) <60 ml/min. Forty
percent of Enterobacteriaceae isolates were an ESBL-producing
or aminoglycoside non-susceptible strain. Therapeutic drug
monitoring of a serum trough concentration (goal ≤3 mg/L) is
recommended 30 minutes prior to the second dose.

creatinine increase of ≥0.5 mg/dL, was 3.6%. Results from
another Phase 2 study comparing PZM to levofloxacin 750
daily for cUTI/AP suggest higher nephrotoxicity when 15 mg/
kg was used compared to 10 mg/kg, although the higher dose
was selected for Phase 3 trials to optimize pharmacokinetic
and pharmacodynamic targets [46]. A Phase 3, open label,
Combating Antibiotic-Resistant Enterobacteriaceae (CARE)
study evaluated plazomicin versus colistin in combination
with meropenem or tigecycline for serious CRE infections (BSI
and HABP/VABP). Results include lower 28-day all-cause
mortality, higher microbiological response rates, and reduced
nephrotoxicity. Authors concluded that plazomicin-based
combination therapy had a better efficacy and safety profile
compared to colistin-based combination regimens [47,48].
Although classwide warnings for nephrotoxicity, ototoxicity,
neuromuscular blockage, and fetal harm were included in
product labeling, the incidence of nephrotoxicity appears to
be reduced compared to colistin or earlier aminoglycosides,
especially when therapeutic drug monitoring is utilized.
In summary, for the two newer beta-lactam agents CAZ-AVI
and MVB, safety and efficacy data appear favorable compared
to older therapies for CRE infections. It Is concerning that
MIC elevations, some conferring resistance to both CAZ-AVI
and MVB, were observed. PZM offers a potential expanded
CRE spectrum of activity and a better safety and efficacy profile
compared to colistin-based combination regimens. Future
studies are needed to optimize protection against antimicrobial
resistance through combination therapy or optimal dosing.’

Antimicrobial Pipeline
Several agents with novel mechanisms of action are in the
antimicrobial development pipeline. Table 2 lists five agents
with Phase 2 and 3 clinical trial data, and likely review for FDA
approval in the near future. Both non-CRE and CRE studies
were included in the table.

Conclusions
CRE infections are a healthcare and public health threat.
Mortality rates are high, and agents with better safety and
efficacy profiles plus expanded carbapenemase activity are
desperately needed. When using older agents, combination
therapy, particularly carbapenem-containing regimens, reduces
mortality with severe infections, but may not have as much of
a benefit with UTIs. Three newer agents, CAZ-AVI, MVB and
PZM, are available and have activity against Class A-producing
Klebsiella pneumoniae, the predominant CRE pathogen in
the United States. In small studies, these agents demonstrate
promising these clinical outcome and mortality data compared
to older agents. However, further studies are needed to
optimize their use (monotherapy versus combination therapy)
and prevent emergence of therapy. Infections caused by MBLs
remain infrequent in the United States, and treatment options
against these strains are sparse. Several antimicrobial agents
are in the pipeline to address this need.
Funding Source: No funding sources declared.
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With regards to adverse effects, in the EPIC study the
incidence of nephrotoxicity in the PZM arm, defined as a serum
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